NASH Clinical Trials 2024

NASH Clinical Trials 2024

NASH research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in non-alcoholic steatohepatitis clinical trials today.

NASH Clinical Trials

Here are the 6 most popular medical studies for nash

Popular filter options for nash trials

Non-alcoholic Fatty Liver Disease Clinical Trials

View 53 Non-alcoholic Fatty Liver Disease medical studies.

NAFLD Clinical Trials

View 52 NAFLD medical studies.

Phase 3 Nash Clinical Trials

View 60 phase 3 nash medical studies.

Nash Clinical Trials With No Placebo

View 60 nash medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to nash

What are the top hospitals conducting nash research?

In the realm of clinical trials for Nonalcoholic Steatohepatitis (NASH), several hospitals have emerged as key players in the battle against this complex liver condition. Located in Lakewood Ranch, Florida, the Florida Research Institute takes a leading role with six active NASH trials and an impressive total of 17 trials dedicated to this disease. Having initiated their first trial in 2016, they are committed to exploring innovative treatment options for patients affected by NASH. Similarly, South Texas Research Institute in Edinburg has also made significant strides with six ongoing NASH trials and a commendable history of 14 completed studies since recording their inaugural trial just two years ago in 2019.

Meanwhile, at Inland Empire Liver Foundation situated in Rialto, California researchers are actively engaged in six NASH clinical trials while having conducted an extensive range of 28 previous investigations since initiating their first one back in 2015. Another prominent player on this list is Tandem Clinical Research located in Marrero which currently runs six active NASH trials alongside a substantial contribution to scientific knowledge through conducting thirteen previous studies; theirs can be traced back only four years ago to2017.The American Research Corporation located within San Antonio may appear slightly smaller-scale but nevertheless plays a crucial part with its five current NASH clinical trials and noteworthy involvement through eleven previously held investigations that began around the same time frame.

These top hospitals spearhead efforts not only to understand and combat NASH but also signify triumphs of medical advancement on both regional and national levels. Each step taken towards unraveling the intricacies surrounding this liver condition brings us closer to discovering effective treatments that could positively impact countless lives worldwide

Which are the best cities for nash clinical trials?

For NASH clinical trials, several cities emerge as top contenders in the field of research and development. San Antonio, Texas leads with an impressive 69 active trials focusing on promising treatments like TERN-501, TVB-2640, and AXA1125. Following closely behind is Miami, Florida with 56 ongoing studies exploring IVA337, Study 1 ALN-HSD Low Dose, Obeticholic Acid, among others. Houston, Texas also plays a notable role in NASH research with 30 active trials investigating TERN-501, TVB-2640, BOS-580 and more. These cities provide crucial platforms for individuals seeking to participate in cutting-edge NASH clinical trials that pave the way for advancements in therapy options and potential breakthroughs in care.

Which are the top treatments for nash being explored in clinical trials?

Cutting-edge research in clinical trials is shedding light on the top treatments for non-alcoholic steatohepatitis (NASH), a liver disease with limited therapeutic options. Two leading contenders include EFX and empagliflozin. EFX, introduced in 2019, has shown promise with two ongoing NASH trials and three all-time trials dedicated to this condition. Similarly, empagliflozin, which made its debut in 2015, is also being explored through two active NASH trials and boasts an impressive record of eight all-time NASH studies. These innovative therapies offer hope for patients battling this complex liver disease as scientists continue to uncover potential breakthroughs.

What are the most recent clinical trials for nash?

Exciting advancements are being made in the field of nash treatment, with recent clinical trials offering hope and potential solutions for patients. One such trial is Part 1 Group 2, a Phase 2 study that aims to evaluate the efficacy and safety of a new intervention for nash. Additionally, BI 3006337 dose group 4, a Phase 1 trial, has shown promise as a potential treatment option for this condition. Pemvidutide at a dosage of 1.2 mg has also demonstrated positive outcomes in Phase 2 studies with nash patients. Furthermore, efinopegdutide at a dosage of 4mg is currently undergoing Phase 2 trials to assess its effectiveness against nash. Finally, TVB-2640 at a dosage of50 mg holds potential as an intervention for individuals with normal hepatic function affected by nash.This ongoing research offers renewed optimism to those living with this challenging disease

What nash clinical trials were recently completed?

In recent years, numerous clinical trials have been completed in the search for effective treatments for nonalcoholic steatohepatitis (NASH). Notable trials include Altimmune's investigation of ALT-801, which concluded in September 2021 and March 2022. Likewise, 89bio's trial on BIO89-100 and Merck Sharp & Dohme Corp.'s study on Efinopegdutide were both finalized in August 2021. Other studies such as Amgen's AMG 609 trial, Terns' TERN-201 trial, and Pfizer's PF-06865571 trial reached completion between May to August of 2021. These groundbreaking efforts highlight the collective commitment towards advancing NASH therapeutics and offer hope for patients grappling with this complex condition.